

To find the nearest patient service center, visit www. labcorp.com or call 888-LABCORP (888-522-2677).

Patient's Legal Name (Last, First, MI)		Sex M F	Date of Birth MO DAY YR	Collection T	ïme Fasting AM ☐ Yes PM ☐ No	Collection Date MO DAY YR	Urine hrs/vol
NPI	Physician's ID#		Patient's ID#		☐ In-Patient	Hospital Patient St	tatus:
Physician's Name (Last, First)	Physician/Autho X	rized Signatu	Patient's  City	Address		Phone	
Diagnosis/Signs/Symptoms in ICD-CM for Highest Specificity RE		vice	<u> </u>	Policy Holder	(if different from	State m patient)	ZIP
PRIMARY BILLING PARTY	SECONDARY BILLI	NG PARTY		of Policy Holde	er		APT #
Insurance Carrier *  ID #	Insurance Carrier *  ID #		City			State	ZIP
Group #	Group #		hereby authorize the lagree to assume r	release of medical inf esponsibility for payn	ormation related to the nent of charges for lai	service described herein and a boratory services that are not	uthorize payment directly to LabCorp covered by my healthcare insurer
Insurance Address	Insurance Address		Patient's Signature				Date
Name of Insured Person	Name of Insured Person		Refer to p	olicies published	by your Medicar	e Administrative Contra	
Relationship to Patient	Relationship to Patient		www.LabCorp.co			/ INDIVIDUAL PROFIL	subject to ABN guidelines.
Employer Name	Employer Name				31#	TEST N.	AMES
*If Medicaid State Physician's Provider		orkers Comp Yes No					

	Carataria Nama	E	Income Manage				1551 #	TEST NAMES	
	Employer Name		loyer Name						
	*If Medicaid State	Physician's Provider #		Workers Comp ☐ Yes ☐ No					
			= 0 !!	CLINICAL IN	NDICATION FO	D TEQ	т		
Date drawn: / /	Specimen Type:	□ Peripheral Blood	☐ Saliva	CLINICAL II	ADICATION TO	K ILS			
Ethnicities (Check all that appl	y):								
□ Caucasian □ Ashke	nazi Jewish	<ul> <li>Sephardic Jewish</li> </ul>	☐ Asian	All diagnages sh	مرط الممارية	the end	ering physician or an authori	and designed	
☐ African American ☐ Native					it in effect at Date of Service		Required)		
Other:		☐ Hispanic	J	ICD-CM	•	ICD-C	M	ICD-CM	
				<b>Family Histo</b>	ory				
Hereditary Cancer BRAC1/2 (	test components	s on back)		Is there a famil	y history of cance	? 🔲	Yes □No □ l	Jnknown	
☐ 485030 BRCAssure®: Comprehension	ve Analysis 🗌 48	5097 BRCAssure®: Ashkenazi	i Jewish Panel	Have any famil		positiv	e for a hereditary cancer	syndrome? \(\superstack \text{Yes}\)	⊔ NO
☐ 485066 BRCAssure®: BRCA1 Targe	eted Analysis* 🔲 48	5050 BRCAssure®: BRCA1/2 [	Deletion/	Please	attach a copy of	the res	sults		
☐ 485081 BRCAssure®: BRCA2 Targeted Analysis* Duplication Analysis				Is the patient a	dopted?		Yes 🗌 No		
* Known familial variant - family mer	nber's results required		J	Please attach p	pedigree or comple	ete tabl	e below. Is a pedigree at	tached?	□ No
Hereditary Cancer Panel (ger	noe included liet	od on back)		Relationship			Relative Available for		Age at
☐ 481220 VistaSeg® Hereditary Cance				(Father, Sister, Aunt, etc.)	Maternal or Pat	ernal	Testing? If no, please state reason	Cancer Type	Diagnosis
■ 481240 VistaSeq® Hereditary Cance				,,					+
■ 481319 VistaSeg® Breast Cancer Pa		7/2 gonoc (20 conc / 1000)							
☐ 481452 VistaSeq® High/Moderate Ri		el (9 Gene Assay)							
481330 VistaSeq® GYN Cancer Pan									
481341 VistaSeq® Breast and GYN				Genetic couns	seling provided:	☐ Yes	□No	•	
☐ 451382 Mutation-specific Sequencin	g Gene(s).	IVIUIALION(S)		If yes, prov	ride counselor na	me:			
OTHER:			<i>)</i>	Phone Nun	nber:				
Patient Clinical Cancer History				Patient un	derstands by	signin	g below:		
No personal history of cancer				LabCorp may us	e information obtained	on this f	orm and other information prov	rided by me and/or my o	rdering provider or
Breast, Invasive or DCIS, age at D	v (Chack a	Il that annly)					my health plan as required. I u	understand a preauthoriz	zation approval fro
	•	☐ Triple Negative (ER-,	DB_ HEB_\	1 '	oes not guarantee full				
	•	_ , , , ,	ric-, ricit-)				ted out-of-pocket cost is more t stimated cost, my actual out-of		
=	☐ Endometrial, Age						contact my health plan regarding		
, 0	Renal, Age at D			☐ If marked, in	the event I cannot be	reached.	LabCorp may leave a confide	ntial voicemail message	at the telephone
	If Prostate Gleason	Score		number prov			,, .,		
Colorectal, Age at Dx				Datiantia Cinn			Tala		
	e 🗆 Low			Patient's Sign	nature (required) _			phone	
IHC Result: ☐ Present ☐ Absen	it IHC of	_					ORMED CONSEN		
Other Cancers, please list		Age(s) of Dx:		'	nave obtained infor	med cor	sent for the above ordered of	genetic test(s). (Requir	ea)
History of Bone Marrow / Stem Ce	ll Transplant			Phy	sician's Signature				
$\square$ History of blood transfusion, date of				Please indic	ate the diagnostic c	enter to	which you want screen pos	itive results reported (	(NY State only)
las the patient had genetic testing fo	or cancer? If yes, ple	ase attach report:							
				When	ordering tests for w	hich Me	dicare or Medicaid reimburs	sements will be sough	t, physicians sho
				order	only those test that	are med	lically necessary for the diag	anosis or treatment of	the patient.

# **TEST COMBINATION / PANEL POLICY**

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the LabCorp® request form. LabCorp encourages clients to contact their local LabCorp representative or LabCorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all LabCorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the appropriate payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. LabCorp will process the specimen for a microbiology test based on source.

#### For assistance with Hereditary Cancer testing and Client Services please call 1-800-345-4363.

Test No.	Description	Specimen	CPTs		Components			
Hereditary C	ancer							
485030	BRCAssure®: Comprehensi BRCA1/2 Analysis	ve one 4 mL LAV	81162		Includes full gene sequent deletion analysis of BF	uencing and duplication/ RCA1/2 genes		
485097	BRCA <i>ssure</i> ®: Ashkenazi Jewish Panel	one 4 mL LAV	81212	three known pathogenic 1 gene, one in BRCA2 gene				
485066	BRCAssure®: BRCA1 Targeted Analysis	one 4 mL LAV	81215		Includes sequencing o on BRCA 1 gene	f known familial mutation(s)		
485081	BRCAssure®: BRCA2 Targeted Analysis	one 4 mL LAV	81217		Includes sequencing o on BRCA 2 gene	f known familial mutation(s)		
485050	BRCAssure®: BRCA1/2 Deletion/duplication analysis	one 4 mL LAV	81164		Deletion/duplication an	alysis of BRCA1/2 genes		
Hereditary C	ancer Panels							
481220	1220 VistaSeq® Hereditary Cancer Panel (27 Gene Assay)		Please go to WWW.LabCorp.com	Please go to WWW.LabCorp.com for CPT description		Components listed below		
481240	VistaSeq <sup>®</sup> Hereditary Cance Panel without <i>BRCA1/2</i> gen (25 Gene Assay)		Please go to WWW.LabCorp.com	for CPT description	Components listed below			
481319	VistaSeq <sup>®</sup> Breast Cancer Panel (19 Gene Assay)	two 4 mL LAV	Please go to WWW.LabCorp.com	for CPT description	Components listed bel	ow		
481452	VistaSeq <sup>®</sup> High/Moderate Risk Breast Cancer Panel (9 Gene Assay)	two 4 mL LAV	Please go to Components listed below WWW.LabCorp.com for CPT description		OW			
481330	VistaSeq <sup>®</sup> GYN Cancer Panel (11 Gene Assay)	two 4 mL LAV	Please go to WWW.LabCorp.com	for CPT description	Components listed bel	ow		
481341	VistaSeq <sup>®</sup> Breast and GYN ( Panel (25 Gene Assay)	Cancer two 4 mL LAV	Please go to WWW.LabCorp.com	for CPT description	Components listed bel	ow		
VistaSeq® Here	editary Cancer Panel Gene Li	st						
APC	BRCA1 <sup>*</sup>	CDK4	FAM175	MUTYH	PRKAR1A	SMAD4		

APC	BRCA1 <sup>*</sup>	CDK4	FAM175	MUTYH	PRKAR1A	SMAD4
ATM	BRCA2 <sup>*</sup>	CDKN2A	MLH1	NBN	PTEN	STK11
BARD1	BRIP1	CHEK2	MSH2	PALB2	RAD51C	TP53
BMPR1A	CDH1	EPCAM	MSH6	PMS2	RAD51D	

<sup>\*</sup> Not included in VistaSeq Hereditary Cancer Panel without BRCA1/2 genes

#### VistaSeq® Breast Panel

ATM	BRCA2	CHEK2	MUTYH	PALB2	RAD51C	TP53
BARD1	BRIP1	FAM175A	NBN	PTEN	RAD51D	
BRCA1	CDH1	MRE11A	NF1	RAD50	STK11	

#### VistaSeq® High/Moderate Risk Breast Panel

ATM	BRCA2	CHEK2	PTEN	TP53	
BRCA1	CDH1	PALB2	STK11		

## VistaSeq® GYN Panel

BRCA1	CHEK2	MLH1	MSH6	PMS2	TP53	
BRCA2	EPCAM	MSH2	MUTYH	PTEN		

### VistaSeg® Breast and GYN Panel

ATM	BRIP1	FAM175A	MSH2	NF1	RAD50	TP53
BARD1	CDH1	FANCC	MSH6	PALB2	RAD51C	
BRCA1	CHEK2	MLH1	MUTYH	PMS2	RAD51D	
BRCA2	EPCAM	MRE11A	NBN	PTEN	STK11	